{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:44:35Z","timestamp":1775695475730,"version":"3.50.1"},"reference-count":28,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Health and Youth Care Inspectorate","award":["2018-06"],"award-info":[{"award-number":["2018-06"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,6,20]]},"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Methylphenidate is a \u2018prescription only\u2019 drug against attention disorders which is increasingly used by adults. We investigated whether methylphenidate in adults was associated with an increased risk of psychiatric events such as depression, and suicide attempt and overall mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A population-based matched cohort design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The Integrated Primary Care Information system, a general practitioners (GP) database in the Netherlands with a source population of 2.5 million inhabitants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>During the study period between 1 June 1996 and 1 January 2018, 8905 adults started methylphenidate and were matched to 10 non-users on sex, age, GP practice and ad prescription date. The total study population consisted of 97 198 participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Serious psychiatric events such as depression and suicide attempts, and overall mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Analyses<\/jats:title>\n                    <jats:p>Risks of development of each event during the use of methylphenidate were expressed as HR with 95% CI, adjusted for relevant confounders with methylphenidate as a time-dependent determinant. Additional adjustment was performed for the intervention (\u2018intention-to-treat\u2019).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Although during follow-up, the unadjusted risks of depression and suicide attempt were strongly increased in users, depression and psychosis became non-significant after adjustment for alcohol-abuse and substance-abuse and psychiatric disease in the medical history and after adjustment for \u2018intention-to-treat\u2019. However, the risk of suicide attempts remained significantly increased after full adjustment (HR 2.0; 95% CI 1.1 to 3.6), and was highest in women and in participants within the age-group of 18\u201340 years. The unadjusted risk of overall mortality was strongly increased, but this lowered to a significant 30% risk increase (HR 1.3; 95% CI 1.1 to 1.6) after full adjustment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There is an increased risk of suicide attempts in adults up to 40 years of age after starting methylphenidate and this risk should be carefully considered before prescribing to this group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-057303","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T11:13:56Z","timestamp":1661512436000},"page":"e057303","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["General practice database on mortality in adults on methylphenidate: cohort study"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-9762","authenticated-orcid":false,"given":"Bruno","family":"Stricker","sequence":"first","affiliation":[{"name":"Epidemiology, Erasmus Medical Center, Rotterdam, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiki","family":"Cheung","sequence":"additional","affiliation":[{"name":"Epidemiology, Erasmus Medical Center, Rotterdam, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8162-4904","authenticated-orcid":false,"given":"Katia","family":"Verhamme","sequence":"additional","affiliation":[{"name":"Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"2025121509370746000_12.8.e057303.1","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bcp.13000","article-title":"Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015","volume":"82","author":"Renoux","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2025121509370746000_12.8.e057303.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03373.x"},{"key":"2025121509370746000_12.8.e057303.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.09.001"},{"key":"2025121509370746000_12.8.e057303.4","article-title":"Immediate-Release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults","volume":"1","author":"C\u00e2ndido","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121509370746000_12.8.e057303.5","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S2215-0366(16)30190-0","article-title":"Method of adult diagnosis influences estimated persistence of childhood ADHD: a systematic review of longitudinal studies","volume":"3","author":"Sibley","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"2025121509370746000_12.8.e057303.6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40263-017-0410-7","article-title":"Cardiovascular effects of stimulant and Non-Stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine","volume":"31","author":"Hennissen","year":"2017","journal-title":"CNS Drugs"},{"key":"2025121509370746000_12.8.e057303.7","unstructured":"lareb. Available: https:\/\/www.lareb.nl\/nl\/ nieuwsoverzicht\/betere-bewaking-veiligheid-methylfenidaat-voor-adhd-bij-volwassenen\/"},{"key":"2025121509370746000_12.8.e057303.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2013.06.004"},{"key":"2025121509370746000_12.8.e057303.9","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.7.709"},{"key":"2025121509370746000_12.8.e057303.10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S2215-0366(19)30189-0","article-title":"Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study","volume":"6","author":"Hollis","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"2025121509370746000_12.8.e057303.11","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/mp.2015.163","article-title":"Psychiatric gene discoveries shape evidence on ADHD\u2019s biology","volume":"21","author":"Thapar","year":"2016","journal-title":"Mol Psychiatry"},{"key":"2025121509370746000_12.8.e057303.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.09.010"},{"key":"2025121509370746000_12.8.e057303.13","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-2486","article-title":"Stimulant medication and psychotic symptoms in offspring of parents with mental illness","volume":"137","author":"MacKenzie","year":"2016","journal-title":"Pediatrics"},{"key":"2025121509370746000_12.8.e057303.14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301164"},{"key":"2025121509370746000_12.8.e057303.15","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2012.169"},{"key":"2025121509370746000_12.8.e057303.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2009.06.005"},{"key":"2025121509370746000_12.8.e057303.17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-10-199311150-00011"},{"key":"2025121509370746000_12.8.e057303.18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1634402"},{"key":"2025121509370746000_12.8.e057303.19","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/13.3.294"},{"key":"2025121509370746000_12.8.e057303.20","article-title":"Drug therapy for the management of cancer related fatigue","author":"Minton","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121509370746000_12.8.e057303.21","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-0185"},{"key":"2025121509370746000_12.8.e057303.22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/JCP.0000000000000406","article-title":"Prescription stimulant use and hospitalization for psychosis or mania: a population-based study","volume":"35","author":"Cressman","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"2025121509370746000_12.8.e057303.23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"2025121509370746000_12.8.e057303.24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.schres.2015.08.033","article-title":"Attention-Deficit\/Hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population-based study in Taiwan","volume":"168","author":"Shyu","year":"2015","journal-title":"Schizophr Res"},{"key":"2025121509370746000_12.8.e057303.25","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.216","article-title":"Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system","volume":"6","author":"Man","year":"2016","journal-title":"Transl Psychiatry"},{"key":"2025121509370746000_12.8.e057303.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813751"},{"key":"2025121509370746000_12.8.e057303.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04167.x"},{"key":"2025121509370746000_12.8.e057303.28","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112408"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-057303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:37:17Z","timestamp":1765820237000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-057303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,26]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1136\/bmjopen-2021-057303"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-057303","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}